Bispecific antibody for ICOS and PD-L1
AssigneeKymab Limited
InventorsMatthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
Life of this patent
Estimating the term…
Abstract
Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
Claims27
A multispecific antibody that binds ICOS and PD-L1 comprising a Fab and an Fc region, wherein the Fab comprises an ICOS binding site and wherein the Fc region comprises a PD-L1 binding site,
- wherein the PD-L1 binding site is provided by a CH3 domain in which residues 14 to 18 are substituted by SGYW (SEQ ID NO:
- 617), residues 45.1 to 78 are substituted by EPQYWA (SEQ ID NO:
- 618), and residues 92 to 101 are substituted by SNWRWQLDD (SEQ ID NO:
- 619).
A multispecific antibody that binds ICOS and PD-L1, comprising a Fab and an Fc region, wherein
- the Fab comprises an ICOS binding site comprising a VH domain amino acid sequence at least 90% identical to SEQ ID NO:
- 408 and a VL domain amino acid sequence at least 90% identical to SEQ ID NO:
- 415, and wherein
- the Fc region comprises a PD-L1 binding site provided by a CH3 domain in which residues 14 to 18 are substituted by SGYW (SEQ ID NO:
- 617), residues 45.1 to 78 are substituted by EPQYWA (SEQ ID NO:
- 618), and residues 92 to 101 are substituted by SNWRWQLDD (SEQ ID NO:
- 619).
A multispecific antibody comprising a Fab and an Fc region,
- wherein the Fab comprises an ICOS binding site
- wherein the Fc region comprises a PD-L1 binding site, wherein the PD-L1 binding site is provided by a CH3 domain in which residues 14 to 18 are substituted by SGYW (SEQ ID NO:
- 617), residues 45.1 to 78 are substituted by EPQYWA (SEQ ID NO:
- 618), and residues 92 to 101 are substituted by SNWRWQLDD (SEQ ID NO:
- 619), and
- wherein the multispecific antibody comprises a heavy chain comprising amino acid sequence SEQ ID NO:
- 621.
Dependencies are inferred from the claim text.